ProQR Therapeutics (PRQR) Non Operating Investment Income (2014 - 2022)
ProQR Therapeutics recorded quarterly Non Operating Investment Income of $625130.1 in Q3 2022, up 388.2% quarter-over-quarter from $128046.8 in Q2 2022, and up 299.28% year-over-year from $156563.4 in Q3 2021.
ProQR Therapeutics' Non Operating Investment Income history runs 9 years deep, the most recent figure standing at $625130.1 for Q3 2022.
- In Q3 2022, Non Operating Investment Income rose 299.28% year-over-year to $625130.1; the TTM figure through Sep 2022 stood at $3.4 million (down 27.07% YoY), while the FY2020 annual figure was $4.2 million, up 1053.51% from the prior year.
- Non Operating Investment Income came in at $625130.1 for Q3 2022 at ProQR Therapeutics, up from $128046.8 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $3.0 million in Q2 2021 to a low of -$1.5 million in Q3 2019.
- A 5-year average of $451483.3 and a median of $86071.6 in 2018 frame the typical range for Non Operating Investment Income.
- On a YoY basis, Non Operating Investment Income climbed as much as 709799.16% in 2019 and fell as far as 53306.63% in 2019.
- ProQR Therapeutics' Non Operating Investment Income stood at $146.1 in 2018, then soared by 709799.16% to $1.0 million in 2019, then surged by 94.51% to $2.0 million in 2020, then sank by 115.55% to -$313690.4 in 2021, then jumped by 299.28% to $625130.1 in 2022.
- According to Business Quant data, Non Operating Investment Income over the past three periods registered $625130.1, $128046.8, and -$313690.4 for Q3 2022, Q2 2022, and Q3 2021 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 230,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | ProQR Therapeutics | 174.11 Mn | 66.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 625,130.08 |
| Sep 30, 2022 | 625,130.08 |
| Jun 30, 2022 | 128,046.80 |
| Jun 30, 2022 | 128,046.80 |
| Sep 30, 2021 | -313,690.43 |
| Sep 30, 2021 | -313,690.43 |
| Jun 30, 2021 | 2.97 Mn |
| Jun 30, 2021 | 2.97 Mn |
| Mar 31, 2021 | 353.43 |
| Mar 31, 2021 | 353.43 |
| Dec 31, 2020 | 2.02 Mn |
| Dec 31, 2020 | 2.02 Mn |
| Sep 30, 2020 | 2.18 Mn |
| Sep 30, 2020 | 2.18 Mn |
| Jun 30, 2020 | 766,616.25 |
| Jun 30, 2020 | 766,616.25 |
| Mar 31, 2020 | -591.71 |
| Mar 31, 2020 | -591.71 |
| Dec 31, 2019 | 1.04 Mn |
| Dec 31, 2019 | 1.04 Mn |
| Sep 30, 2019 | -1.53 Mn |
| Sep 30, 2019 | -1.53 Mn |
| Jun 30, 2019 | 596,652.36 |
| Jun 30, 2019 | 596,652.36 |
| Mar 31, 2019 | -561,494.66 |
| Mar 31, 2019 | -561,494.66 |
| Dec 31, 2018 | 146.10 |
| Dec 31, 2018 | 146.10 |
| Sep 30, 2018 | 86,071.56 |
| Sep 30, 2018 | 86,071.56 |
| Jun 30, 2018 | -321,036.55 |
| Jun 30, 2018 | -321,036.55 |
| Mar 31, 2018 | 1,055.31 |
| Mar 31, 2018 | 1,055.31 |
| Dec 31, 2017 | 689.98 |
| Dec 31, 2017 | 689.98 |
| Sep 30, 2017 | 1,019.95 |
| Sep 30, 2017 | 1,019.95 |
| Jun 30, 2017 | 1.30 Mn |
| Jun 30, 2017 | 1.30 Mn |
| Mar 31, 2017 | 572.12 |
| Mar 31, 2017 | 572.12 |
| Sep 30, 2016 | 283.51 |
| Sep 30, 2016 | 283.51 |
| Sep 30, 2015 | 55.61 |
| Sep 30, 2015 | 55.61 |
| Mar 31, 2015 | -7.89 Mn |
| Mar 31, 2015 | -7.89 Mn |
| Mar 31, 2014 | 86,333.03 |
| Mar 31, 2014 | 86,333.03 |